Read by QxMD icon Read

Journal of the International AIDS Society

Barbara Laughton, Morna Cornell, Martin Kidd, Priscilla Estelle Springer, Els Françoise Marie-Thérèse Dobbels, Anita Janse Van Rensburg, Kennedy Otwombe, Abdel Babiker, Diana M Gibb, Avy Violari, Mariana Kruger, Mark Fredric Cotton
INTRODUCTION: Early antiretroviral therapy (ART) has improved neurodevelopmental outcomes of HIV-infected (HIV-positive) children; however, little is known about the longer term outcomes in infants commencing early ART or whether temporary ART interruption might have long-term consequences. In the children with HIV early antiretroviral treatment (CHER) trial, HIV-infected infants ≤12 weeks of age with CD4 ≥25% were randomized to deferred ART (ART-Def); immediate time-limited ART for 40 weeks (ART-40W) or 96 weeks (ART-96W)...
May 2018: Journal of the International AIDS Society
Phillip Keen, Richard T Gray, Barbara Telfer, Rebecca Guy, Heather-Marie Schmidt, Bill Whittaker, Jo Holden, Martin Holt, Anthony Kelleher, David Wilson, Denton Callander, David A Cooper, Garrett Prestage, Christine Selvey, Andrew E Grulich
INTRODUCTION: The HIV Strategy in New South Wales (NSW) Australia aims to virtually eliminate HIV transmission by 2020. We estimated the 2016 HIV diagnosis and care cascade for the state of NSW, with a focus on introducing population-based data to improve data quality and assess progress towards the UNAIDS 90-90-90 targets. METHODS: To estimate the number of people living with diagnosed HIV (PLDHIV) we used NSW data from the Australian National HIV Registry, enhanced by surveillance among people recently diagnosed with HIV to improve migration estimates...
April 2018: Journal of the International AIDS Society
Edward A Oladele, Okikiolu A Badejo, Christopher Obanubi, Emeka F Okechukwu, Ezekiel James, Golden Owhonda, Onuche I Omeh, Moyosola Abass, Olubunmi R Negedu-Momoh, Norma Ojehomon, Dorothy Oqua, Satish Raj-Pandey, Hadiza Khamofu, Kwasi Torpey
INTRODUCTION: Significant gaps persist in providing HIV treatment to all who are in need. Restricting care delivery to healthcare facilities will continue to perpetuate this gap in limited resource settings. We assessed a large-scale community-based programme for effectiveness in identifying people living with HIV and linking them to antiretroviral treatment. METHODS: A retrospective secular trend study of 14 high burden local government areas of Nigeria was conducted in which two models of community antiretroviral treatment delivery were implemented: Model A (on-site initiation) and Model B (immediate referral) clusters...
April 2018: Journal of the International AIDS Society
(no author information available yet)
No abstract text is available yet for this article.
April 2018: Journal of the International AIDS Society
Divya Mallampati, Rachel L MacLean, Roger Shapiro, Francois Dabis, Barbara Engelsmann, Kenneth A Freedberg, Valeriane Leroy, Shahin Lockman, Rochelle Walensky, Nigel Rollins, Andrea Ciaranello
INTRODUCTION: In 2010, the WHO recommended women living with HIV breastfeed for 12 months while taking antiretroviral therapy (ART) to balance breastfeeding benefits against HIV transmission risks. To inform the 2016 WHO guidelines, we updated prior research on the impact of breastfeeding duration on HIV-free infant survival (HFS) by incorporating maternal ART duration, infant/child mortality and mother-to-child transmission data. METHODS: Using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-Infant model, we simulated the impact of breastfeeding duration on 24-month HFS among HIV-exposed, uninfected infants...
April 2018: Journal of the International AIDS Society
Robyn M Stuart, Laura Grobicki, Hassan Haghparast-Bidgoli, Jasmina Panovska-Griffiths, Jolene Skordis, Olivia Keiser, Janne Estill, Zofia Baranczuk, Sherrie L Kelly, Iyanoosh Reporter, David J Kedziora, Andrew J Shattock, Janka Petravic, S Azfar Hussain, Kelsey L Grantham, Richard T Gray, Xiao F Yap, Rowan Martin-Hughes, Clemens J Benedikt, Nicole Fraser-Hurt, Emiko Masaki, David J Wilson, Marelize Gorgens, Elizabeth Mziray, Nejma Cheikh, Zara Shubber, Cliff C Kerr, David P Wilson
INTRODUCTION: With limited funds available, meeting global health targets requires countries to both mobilize and prioritize their health spending. Within this context, countries have recognized the importance of allocating funds for HIV as efficiently as possible to maximize impact. Over the past six years, the governments of 23 countries in Africa, Asia, Eastern Europe and Latin America have used the Optima HIV tool to estimate the optimal allocation of HIV resources. METHODS: Each study commenced with a request by the national government for technical assistance in conducting an HIV allocative efficiency study using Optima HIV...
April 2018: Journal of the International AIDS Society
Laura Fuente-Soro, Elisa Lopez-Varela, Orvalho Augusto, Charfudin Sacoor, Ariel Nhacolo, Nely Honwana, Esmeralda Karajeanes, Paula Vaz, Denise Naniche
INTRODUCTION: Awareness of HIV-infection goes beyond diagnosis, and encompasses understanding, acceptance, disclosure and initiation of the HIV-care. We aimed to characterize the HIV-positive population that underwent repeat HIV-testing without disclosing their serostatus and the impact on estimates of the first UNAIDS 90 target. METHODS: This analysis was nested in a prospective cohort established in southern Mozambique which conducted three HIV-testing modalities: voluntary counselling and testing (VCT), provider-initiated counselling and testing (PICT) and home-based testing (HBT)...
April 2018: Journal of the International AIDS Society
Richard T Gray, David P Wilson, Rebecca J Guy, Mark Stoové, Margaret E Hellard, Garrett P Prestage, Toby Lea, John de Wit, Martin Holt
INTRODUCTION: We determined the contribution of undiagnosed HIV to new infections among gay and bisexual men (GBM) over a 12-year period in Australia where there has been increasing focus on improving testing and HIV treatment coverage. METHODS: We generated annual estimates for each step of the HIV cascade and the number of new HIV infections for GBM in Australia over 2004 to 2015 using relevant national data. Using Bayesian melding we then fitted a quantitative model to the cascade and incidence estimates to infer relative transmission coefficients associated with being undiagnosed, diagnosed and not on ART, on ART with unsuppressed virus, or on ART with suppressed virus...
April 2018: Journal of the International AIDS Society
Céline Grillon, Priti R Krishtel, Othoman Mellouk, Anton Basenko, James Freeman, Luís Mendão, Isabelle Andrieux-Meyer, Sébastien Morin
INTRODUCTION: Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV - regardless of HIV status. However, patents and high prices have created access barriers for people living with HCV, especially people who inject drugs (PWID)...
April 2018: Journal of the International AIDS Society
Anders Boyd, Léa Duchesne, Karine Lacombe
INTRODUCTION: The World Health Organization has aimed for global elimination of both hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030. Treatments available to cure HCV and control HBV, as well as vaccination to prevent HBV infection, have certainly allowed for such bold goals, yet the final steps to usher in elimination require further evidence. DISCUSSION: We broadly discuss the needs for three major public health approaches. First, an effective vaccine exists for HBV and mass-vaccination campaigns have resulted in decreases in hepatitis B surface antigen seroprevalence and overall rates of liver-related morality...
April 2018: Journal of the International AIDS Society
Jeffrey V Lazarus, Samya R Stumo, Magdalena Harris, Greet Hendrickx, Kristina L Hetherington, Mojca Maticic, Marie Jauffret-Roustide, Joan Tallada, Kaarlo Simojoki, Tatjana Reic, Kelly Safreed-Harmon
INTRODUCTION: The first World Health Organization (WHO) global health sector strategy on hepatitis B and C viruses (HBV and HCV) has called for the elimination of viral hepatitis as a major public health threat by 2030. This study assesses policies and programmes in support of elimination efforts as reported by patient groups in Europe. METHODS: In 2016 and 2017, hepatitis patient groups in 25 European countries participated in a cross-sectional survey about their countries' policy responses to HBV and HCV...
April 2018: Journal of the International AIDS Society
Slim Fourati, Jordan J Feld, Stéphane Chevaliez, Niklas Luhmann
INTRODUCTION: In the light of the advances in HCV antiviral therapy, global control of HCV infection becomes feasible but depends on the capacity of countries to identify infected people and to offer them treatment. To achieve the WHO goal which targets a diagnosis rate of 90% by 2030, simplification of screening and diagnosis will be crucial. METHODS: Published literature, unpublished data and expert consensus were used to determine key parameters, including point-of-care, rapid diagnostic testing, screening, the use of HCV core Ag and dried blood spots; starting from 2008 until November 2017...
April 2018: Journal of the International AIDS Society
Natasha K Martin, Anne Boerekamps, Andrew M Hill, Bart J A Rijnders
INTRODUCTION: The World Health Organization targets for hepatitis C virus (HCV) elimination include a 90% reduction in new infections by 2030. Our objective is to review the modelling evidence and cost data surrounding feasibility of HCV elimination among people living with HIV (PLWH), and identify likely components for elimination. We also discuss the real-world experience of HCV direct acting antiviral (DAA) scale-up and elimination efforts in the Netherlands. METHODS: We review modelling evidence of what intervention scale-up is required to achieve WHO HCV elimination targets among HIV-infected (HIV+) people who inject drugs (PWID) and men who have sex with men (MSM), review cost-effectiveness of HCV therapy among PLWH and discuss economic implications of elimination...
April 2018: Journal of the International AIDS Society
Rachel Sacks-Davis, Joseph S Doyle, Andri Rauch, Charles Beguelin, Alisa E Pedrana, Gail V Matthews, Maria Prins, Marc van der Valk, Marina B Klein, Sahar Saeed, Karine Lacombe, Nikoloz Chkhartishvili, Frederick L Altice, Margaret E Hellard
INTRODUCTION: There is currently no published data on the effectiveness of DAA treatment for elimination of HCV infection in HIV-infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This research aims to report cascade of care data for emerging HCV elimination initiatives and studies that are currently being evaluated in HIV/HCV co-infected populations in the context of implementation science theory. METHODS: HCV elimination initiatives and studies in HIV co-infected populations that are currently underway were identified...
April 2018: Journal of the International AIDS Society
Karine Lacombe, Marina B Klein
No abstract text is available yet for this article.
April 2018: Journal of the International AIDS Society
Alessio Aghemo, Lionel Piroth, Sanjay Bhagani
INTRODUCTION: The introduction of drugs targeting the virus replication cycle has revolutionized treatment of chronic hepatitis C virus. These drugs, called direct-acting antivirals, have brought about extremely high rates of virological cure and have increased the number of patients who can receive treatment due to the lack of absolute contraindications. A combination of different classes of direct-acting antivirals is the current standard of care. Although treatment administration and monitoring has been simplified in recent years, it is still relatively complex and mostly in the hands of specialists...
April 2018: Journal of the International AIDS Society
Yvan J-F Hutin, Marc Bulterys, Gottfried O Hirnschall
INTRODUCTION: In 2016, the Global Health Sector Strategy (GHSS) on viral hepatitis called for elimination of viral hepatitis as a major public health threat by 2030 (i.e. 90% reduction in incidence and 65% in mortality). In 2017, WHO's first-ever Global Hepatitis Report presented the baseline values for each of the core indicators of the strategy. We review the challenges and opportunities that lie ahead in order to reach the 2030 service coverage targets. DISCUSSION: Three-dose coverage of hepatitis B vaccine in infancy reached 84% in 2015 (2030 target: 90%); however, only 39% received the timely birth dose (2030 target: 90%)...
April 2018: Journal of the International AIDS Society
Elske Hoornenborg, Roel Ca Achterbergh, Maarten F Schim van der Loeff, Udi Davidovich, Jannie J van der Helm, Arjan Hogewoning, Yvonne Thp van Duijnhoven, Gerard Jb Sonder, Henry Jc de Vries, Maria Prins
INTRODUCTION: The Amsterdam PrEP project is a prospective, open-label demonstration study at a large sexually transmitted infection (STI) clinic. We examined the uptake of PrEP; the baseline characteristics of men who have sex with men (MSM) and transgender persons initiating PrEP; their choices of daily versus event-driven PrEP and the determinants of these choices. METHODS: From August 2015 through May 2016, enrolment took place at the STI clinic of the Public Health Service of Amsterdam, the Netherlands...
March 2018: Journal of the International AIDS Society
Paula M Luz, Benjamin Osher, Beatriz Grinsztejn, Rachel L Maclean, Elena Losina, Madeline E Stern, Claudio J Struchiner, Robert A Parker, Kenneth A Freedberg, Fabio Mesquita, Rochelle P Walensky, Valdilea G Veloso, A David Paltiel
INTRODUCTION: Men who have sex with men (MSM) and transgender women (TGW) in Brazil experience high rates of HIV infection. We examined the clinical and economic outcomes of implementing a pre-exposure prophylaxis (PrEP) programme in these populations. METHODS: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International model of HIV prevention and treatment to evaluate two strategies: the current standard of care (SOC) in Brazil, including universal ART access (No PrEP strategy); and the current SOC plus daily tenofovir/emtracitabine PrEP (PrEP strategy) until age 50...
March 2018: Journal of the International AIDS Society
Angela M Parcesepe, Catrina Mugglin, Fred Nalugoda, Charlotte Bernard, Evy Yunihastuti, Keri Althoff, Antoine Jaquet, Andreas D Haas, Stephany N Duda, C William Wester, Denis Nash
INTRODUCTION: Integration of services to screen and manage mental health and substance use disorders (MSDs) into HIV care settings has been identified as a promising strategy to improve mental health and HIV treatment outcomes among people living with HIV/AIDS (PLWHA) in low- and middle-income countries (LMICs). Data on the extent to which HIV treatment sites in LMICs screen and manage MSDs are limited. The objective of this study was to assess practices for screening and treatment of MSDs at HIV clinics in LMICs participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium...
March 2018: Journal of the International AIDS Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"